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Inflammatory responses occur within tissue microenvironments, with functional
contributions from both haematopoietic (lymphocytic) cells and stromal cells
(including macrophages and fibroblasts). These environments are complex – a
compound of many different cell types at different stages of activation and
differentiation. Traditional models of inflammatory disease highlight the role of
antigen-specific lymphocyte responses and attempt to identify causative
agents. However, recent studies have indicated the importance of tissue
microenvironments and the innate immune response in perpetuating the
inflammatory process. The prominent role of stromal cells in the generation
and maintenance of these environments has begun to challenge the primacy
of the lymphocyte in regulating chronic inflammatory processes. Sensible
enquiries into factors regulating the persistence of inflammatory disease
necessitate an understanding of the mechanisms regulating tissue homeostasis
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Inflammatory responses resulting from tissue
injury or infection generally result in a beneficial,
self-limiting, healing process. The classical
macroscopic features of inflammation as
described 2000 years ago by the Roman physician
Celsus are rubor (redness), tumour (swelling),
colour (heat) and dolour (pain), and reflect the
underlying molecular and cellular processes –
specifically the release of inflammatory mediators
leading to localised recruitment of immune
effector cells including neutrophils, monocytes
and lymphocytes. These responses can be defined
by three important characteristics: spatial
distribution (site specificity), the identity of the
inflammatory infiltrate (cell type and magnitude
of influx), and temporal pattern (resolving versus
persistent).
Contrasting acute and chronic
inflammation
Defining acute and chronic inflammation might
seem at first a straightforward process: acute
inflammation presents as a short-lived process
with complete resolution; by contrast, chronic
inflammation presents as a long-lasting
phenomenon associated with tissue hyperplasia
and scarring. In practice, this segregation is not
always clear. Gout, for example, can manifest
clinically as a recurrent acute inflammatory lesion,
lasting many years, whereas a tuberculin PPD
(purified protein derivative of tuberculin) skin test
is a chronic inflammatory process that resolves
completely within a few weeks.
A histological definition (acute inflammation
characterised by a neutrophilic infiltrate; chronic
inflammation characterised by a mainly
mononuclear infiltrate), in combination with the
clinical picture (resolution versus persistence), is
probably more useful. Thus, inflammation can be
seen as being either acute resolving, acute
persistent, chronic resolving or chronic persistent.
Recruitment of leukocytes in inflammation is
characterised by an initial infiltration of
neutrophils, present within an hour of the
initiating stimulus. This phase is later replaced by
a more sustained influx of mononuclear cells. One
of the biological consequences of this perivascular
accumulation of mononuclear cells is a change in
the appearance of endothelial cells, which adopt
a structure more like high endothelial venules,
normally seen only in lymphoid tissue (Ref. 1).
The molecular mechanisms controlling the
switch from acute to chronic inflammation are
becoming clearer. Cytokines and chemokines –
proteins that participate in the conversation
between immune and stromal cells – appear to
play a particularly important role in this
process. The chemokines form a superfamily
of structurally related proteins subdivided into
four subfamilies based on the arrangement of
N-terminal cysteine residues (C, CC, CXC and
CX3C families, respectively) (Table 1) (Ref. 2). They
act functionally to regulate tissue homeostasis
and direct responses in both haematopoietic
and stromal cells. A study monitoring the
evolution of the leukocytic infiltrate in peritoneal
inflammation (Ref. 3) has suggested that the
interaction between interleukin 6 (IL-6) and its
soluble receptor sIL-6R forms one of the major
determinants of this temporal switch (Switch 1,
Fig. 1). sIL-6R, produced by the infiltrating
neutrophils, forms a complex with IL-6 and has
the capacity to activate cells lacking expression
of the cognate IL-6 receptor. This mechanism was
shown to modulate CC and CXC chemokine
expression directly. CXC chemokine expression
induced by proinflammatory cytokines [IL-1
and tumour necrosis factor α (TNF-α)] was
suppressed, whereas expression of the CC
chemokine monocyte chemoattractant protein 1
(MCP-1; CCL2) was promoted. This chemokine
shift suppresses further neutrophil recruitment
and promotes a sustained mononuclear cell influx.
Similarly, a study investigating the dynamics of
and remodelling during inflammation. This article highlights recent insights
into the factors regulating dynamic aspects of inflammation, focusing
particularly on mononuclear cell infiltrates, their interactions with stromal cells
in tissues and the relevance of these interactions to existing and possible future
therapies. A key feature of current research has been a growing appreciation
that disordered spatial and temporal interactions between infiltrating immune
cells and resident stromal cells lie at the heart of disease persistence.
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Table 1. Chemokine nomenclaturea (tab001cbb)
Systematic name Original ligand name Receptors
CXC chemokines
CXCL1 GROα CXCR2, CXCR
CXCL2 GROβ CXCR2
CXCL3 GROγ CXCR2
CXCL4 PF4 Unknown
CXCL5 ENA-78 CXCR2
CXCL6 GCP-2 CXCR1, CXCR2
CXCL7 NAP-2 CXCR2
CXCL8 IL-8 CXCR1, CXCR2
CXCL9 Mig CXCR3
CXCL10 IP-10 CXCR3
CXCL11 I-TAC CXCR3
CXCL12 SDF-1α/β CXCR4
CXCL13 BCA-1 CXCR5
CXCL14 BRAK Unknown
CXCL15 Unknown Unknown
CXCL16 – CXCR6
C chemokines
XCL1 Lymphotactin/SCM-1α XCR1
XCL2 SCM-1β XCR1
CX3C chemokines
CX3CL1 Fractalkine CX3CR1
CC chemokines
CCL1 I-309 CCR8
CCL2 MCP-1 CCR2
CCL3 MIP-1α CCR1, CCR5
CCL3L1 LD78β CCR1, CCR5
CCL4 MIP-1β CCR5
CCL5 RANTES CCR1, CCR3, CCR5
CCL6 Unknown Unknown
CCL7 MCP3 CCR1, CCR2, CCR3
CCL8 MCP-2 CCR3, CCR5
CCL9/CCL10 Unknown CCR1
CCL11 Eotaxin CCR3
CCL12 Unknown CCR2
CCL13 MCP-4 CCR2, CCR3
CCL14  HCC-1 CCR1, CCR5
CCL15 HCC-2/Lkn-1/MIP-1δ CCR1, CCR
CCL16 HCC-4/LEC/LCC-1 CCR1, CCR2
CCL17 TARC CCR4
CCL18 DC-CK1 Unknown
CCL19 MIP-3β/ELC CCR7
CCL20 MIP-3α/LARC CCR6
CCL21 6Ckine/SLC CCR7
CCL22 MDC CCR4
CCL23 MPIF-1/CKb8 CCR1
CCL24 Eotaxin-2 CCR3
CCL25 TECK CCR9
CCL26 Eotaxin-3 CCR3
CCL27 CTACK CCR10
CCL28 MEC CCR3/CCR10
a The new nomenclature for human cytokines is detailed. Adapted from Ref. 95.
(for abbreviations see next page)
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Figure 1. Two switches are involved in the development of persistent chronic inflammation. Both acute
and chronic inflammation are characterised by an initial infiltration of neutrophils, followed by a more sustained
influx of mononuclear cells. Neutrophils produce soluble IL-6 receptor (sIL-6R), which binds IL-6 produced by
haematopoietic and stromal cells in the vicinity. The change from a neutrophilic to a mononuclear population
requires a switch from CXC to CC chemokines (Switch 1), and this is regulated by IL-6. (RANTES, also
produced by haematopoietic and stromal cells, is an alternative regulator of this switch, but the exact molecular
mechanism involved remains unclear.) In this way, the nature of the inflammatory infiltrate is tailored to the
inflammatory stimulus, such that the appropriate quantity and quality of leukocyte subsets are recruited. For
the inflammatory infiltrate to resolve completely, a second switch must occur that allows infiltrating cells to die
and be cleared (Switch 2). This becomes disordered, and persistent chronic inflammation results, when cytokines
such as interferon β (IFN-β) and chemokines such as stromal-cell-derived factor 1 (SDF-1) are ectopically
produced by stromal cells such as macrophages and fibroblasts (see also Fig. 3). As shown by the histological
sections, persistent inflammation is associated with an abnormal increase in the number and distribution of
leukocytes within the tissue, classically as a perivascular infiltrate (fig001cbb).
Abbreviations for Table 1 (tab001cbb)
BCA-1, B-cell-attracting chemokine 1; CTACK, cutaneous T-cell-attracting chemokine; DC-CK1, dendritic-
cell-derived CC chemokine 1; ELC, EBL-1-ligand chemokine; ENA-78, epithelial-cell-derived neutrophil
attractant 78; GCP, granulocyte chemotactic protein; GRO, growth-related oncogene; HCC, haemofiltrate
CC chemokine; IL, interleukin; IP-10, interferon-inducible protein 10; I-TAC, interferon-inducible T-cell alpha
chemoattractant; LARC, liver- and activation-regulated chemokine; LEC, liver-expressed chemokine; LCC-1,
liver-specific CC chemokine-1; Lkn-1, leukotactin; MCP, monocyte chemoattractant protein; MDC,
macrophage-derived chemokine; MEC, mammary-enriched chemokine; Mig, monokine induced by
interferon γ; MIP, macrophage inflammatory protein; MPIF, myeloid progenitor inhibitory factor; NAP,
neutrophil-activating peptide; PF4, platelet factor 4; RANTES, ‘regulated on activation, normally T-cell-
expressed and -secreted’; SCM-1α/β, single C motif-1 α/β; SDF, stromal-cell-derived factor; SLC, secondary
lymphoid tissue chemokine; TARC, thymus- and activation-regulated chemokine; TECK, thymus-expressed
chemokine.
Two switches are involved in the development of persistent chronic inflammation
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the inflammatory infiltrate in a rat colitis model
(Ref. 4) found that the CC chemokine RANTES
(CCL5) is important in the progression to
chronic disease. Markedly elevated levels of this
chemokine were found in the chronic phase of the
disease, with elevation of two of its key receptors
(CCR1 and CCR5). Together, these studies suggest
that the cellular switch from an acute to a chronic
inflammatory process is partially chemokine
mediated (Switch 1, Fig. 1), with a CXC to CC shift
leading to a preferential influx of mononuclear
cells at the site of inflammation. Furthermore, they
suggest that cytokines and chemokines made by
infiltrating leukocytes and resident stromal cells
contribute to this switch. Other factors contribute
to the segregation of a chronic resolving process
from a chronic persistent inflammatory process
(during Switch 2), and these are detailed later.
The anatomy of an inflammatory
infiltrate
The role of the endothelium
To achieve efficient immune surveillance and
longstanding immunity, lymphocytes
continuously recirculate through tissues via the
bloodstream, across resting endothelium and into
efferent lymphatics (Ref. 5). On the basis of the
environment in which they first encounter
antigen, lymphocytes acquire a predilection to
home to, and recirculate through, that same
environment (Ref. 6). The mechanisms whereby
such specificity is acquired are unclear, but
probably depend on stromal factors. For example,
it was recently shown that the expression of
chemokine receptors defining tissue tropism is
present within two days of immunisation and that
site specificity is acquired by interactions with
stromal elements present within secondary
lymphoid tissue (Refs 7, 8).
Cellular recruitment to tissues is not random,
but depends on a carefully choreographed
sequence of molecular interactions, involving
leukocyte activation, adhesion, chemoattraction
and endothelial transmigration (see the article and
video on the liver as a model of lymphocyte
recruitment published recently in this journal:
Ref. 9). Extensive experimental evidence supports
the ‘area-code’ model of lymphocyte homing.
This model proposes a cascade of sequential
and combinatorial steps whereby appropriate
leukocyte subsets leave the peripheral circulation
and enter tissues via post-capillary venules
(Ref. 10). Expression of adhesion molecules and
chemoattractant receptors on lymphocytes, and
corresponding ligands for these receptors on
tissue cells, plays a key role in positioning and
retaining lymphocytes within tissues (Ref. 5).
Superimposed on this ‘physiological’ homing
and recirculation of lymphocytes is the
recruitment of immune cells to inflammatory sites
– a key component of the inflammatory response.
By contrast to the situation during leukocyte
homing and recirculation, leukocyte recruitment
during inflammation occurs across activated
systemic vascular endothelium (Ref. 11). The
anatomical location and nature of the
inflammatory insult determine the recruitment
pattern of leukocyte subsets and govern whether
lymphocytes, monocytes, neutrophils or
eosinophils predominate. The most striking
examples of this are the marked accumulation of
eosinophils at extravascular sites of allergic
reaction in the lung in asthma (Ref. 12) and in the
inflammatory diseases of the skin (dermatoses)
(Ref. 13).
With the cloning of the molecules involved in
lymphocyte homing during normal physiological
responses and leukocyte recruitment during
inflammation (Ref. 11), it became apparent that,
at the molecular level, the regulation of these
two distinct yet biologically related processes
are strikingly similar. For example, E-selectin
expressed by endothelial cells binds both
neutrophils during acute inflammation [via E-
selectin ligand 1 (ESL-1)] and skin-homing
memory cells during T-cell homing to the skin [via
cutaneous lymphocyte antigen (CLA)] (Ref. 14).
Both processes rely on transient interactions
between leukocytes and endothelium, a process
termed ‘rolling’. These contacts permit sampling
for activating factors, particularly chemokines that
bind to G-protein-coupled receptors on the rolling
cell (Ref. 15). Reversible arrest, firm adhesion
and migration across the endothelium into tissue
then follow, mediated by additional adhesion
molecules and chemokines (Ref. 16).
The role of stromal-cell-derived
chemokines
Tissue-associated chemokine gradients also direct
cellular localisation. Chemokines are important
molecular signposts, playing an important role in
cell exit from the circulation and retention within
tissues (Ref. 5). The proinflammatory activities of
chemokines have been appreciated for many
years, but recent studies (Refs 5, 17) have
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Figure 2. Chemokine receptors and chemokine ligand specificity (see next page for legend) (fig002cbb).
Chemokine receptors and chemokine ligand specificity
Published in Expert Reviews in Molecular Medicine by Cambridge University Press 2002
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demonstrated that chemokines also provide the
molecular basis for many homeostatic non-
inflammatory functions, including T- and B-cell
development, lymphoid trafficking and T- and B-
cell compartmentalisation within primary and
secondary lymphoid tissues. This has led to a
functional segregation of chemokines (Fig. 2) into
‘inflammatory’ (also called inducible) chemokines
and ‘homeostatic’ (constitutive, housekeeping or
lymphoid) chemokines (Ref. 18). The former
group are produced following stimulation by
proinflammatory cytokines or during direct
pathogen contact, and promote the recruitment
of effector cells (neutrophils, monocytes and
effector T cells) (Ref. 18). The latter group are
expressed constitutively at homing sites and act
on receptors principally found on lymphocytes
(Ref. 19). This functional segregation is not
absolute, as several chemokines have overlapping
functions, including macrophage-derived
chemokine (MDC; CCL22), thymus- and
activation-regulated chemokine (TARC; CCL17)
and liver- and activation-regulated chemokine
(LARC; CCL20) (Ref. 20). Nonetheless, the
classification is conceptually useful.
The interaction of a particular chemokine,
stromal-cell-derived factor 1 (SDF-1; CXCL12),
with its receptor CXCR4 is important in regulating
leukocyte development and retention within
lymphoid tissue. Embryonic disruption of the
genes for SDF-1 or CXCR4 results in death in
utero, with evidence of defective red and white
blood cell formation (Refs 21, 22). SDF-1 is a
chemoattractant for T and B cells with important
roles in the bone marrow (BM), thymus and
secondary lymphoid organs. Production of
SDF-1 by BM stromal cells attracts B-cell
precursors to the BM, where they mature under
the influence of growth and differentiation factors
(Ref. 23). Thymic production of SDF-1 also
appears important, determining the distribution
of particular thymocyte subsets (Ref. 24).
Lymphocyte migration into secondary
lymph nodes and the generation of secondary
lymphoid structures is regulated by B-cell-
activating chemokine (BCA-1; CXCL13), which
acts on CXCR5, and secondary lymphoid tissue
chemokine (SLC; CCL21) and EBL-1-ligand
chemokine (ELC; CCL19), which both act on
CCR7 (Ref. 17). SLC is expressed by high
endothelial venules and attracts CCR7-bearing
lymphocytes. SLC and ELC present in the
parafollicular area regulate T-cell migration,
whereas CXCR5-expressing B cells migrate
further to the BCA-1-expressing follicles (Ref. 17).
Less is known about the molecules that
regulate monocyte trafficking, but recent
evidence suggests that ‘breast and kidney
expressed chemokine’ (BRAK; CXCL14),
produced by a range of stromal tissues, is
selectively chemotactic for activated monocytes
(Ref. 25). Prostaglandin-induced activation
modulates chemokine responsiveness: as BRAK
responsiveness increases, the response to
traditional monocyte chemoattractants MCP-1,
RANTES and SDF-1 decreases. This mechanism
might promote monocyte colocalisation with
BRAK-producing stromal cells, providing
factors important for monocytic differentiation
(Refs 25, 26).
Combinations of adhesion molecules impart
tissue tropism, with additional contributions
Figure 2. Chemokine receptors and chemokine ligand specificity. Chemokine receptors are grouped
according to their specificity for inflammatory chemokines (red boxes) or constitutive chemokines (blue boxes).
Their cellular expression is shown by green boxes. Some constitutive chemokines or chemokine receptors
have shown heterogeneous expression patterns (red/blue boxes). Some chemokine receptors are only
expressed by subsets of certain cells (half-coloured boxes). The work summarised here is constantly being
updated and is an intense area of investigation. Figure reproduced from Ref. 96, with permission from Elsevier
Science (© Copyright 1998, Elsevier Science). Abbreviations: BCA-1, B-cell-attracting chemokine 1; CTACK,
cutaneous T-cell-attracting chemokine; DC, dendritic cell; ELC, EBL-1-ligand chemokine; ENA, epithelial-cell-
derived neutrophil attractant 78; GCP, granulocyte chemotactic protein; GRO, growth-related oncogene; HCC,
haemofiltrate CC chemokine; IL, interleukin; IP-10, interferon-inducible protein 10; I-TAC, interferon-inducible
T-cell alpha chemoattractant; LARC, liver- and activation-regulated chemokine; MCP, monocyte chemoattractant
protein; MEC, mammary-enriched chemokine; Mig, monokine induced by interferon γ; MIP, macrophage
inflammatory protein; MPIF, myeloid progenitor inhibitory factor; NAP, neutrophil-activating peptide; NK, natural
killer; RANTES, ‘regulated on activation, normally T-cell-expressed and -secreted’; SDF, stromal-cell-derived
factor; SLC, secondary lymphoid tissue chemokine; TARC, thymus- and activation-regulated chemokine; TECK,
thymus-expressed chemokine; Th, T helper (fig002cbb).
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from chemokine and chemokine receptor
interactions (Ref. 26). Skin-homing T cells
express CLA and leukocyte function-associated
antigen 1 (LFA-1), which bind to E-selectin and
intercellular cell adhesion molecules (ICAMs),
respectively, on dermal venules of the skin (Ref.
27). Some circulating CLA+ memory T cells
express CCR4, and the respective ligands TARC
and MDC are expressed predominately on the
cutaneous vasculature (Ref. 28). These interactions
contribute to the preferential recruitment of skin-
homing memory T cells. By contrast, gut-homing
cells lack CLA, but express α4β7, the receptor for
mucosal addressin cell adhesion molecule 1
(MAdCAM-1) found on the intestinal vasculature;
these cells also express CCR9, implicated in
homing to intestinal tissues (Ref. 5).
Stromal determinants of inflammatory
cell survival and retention at sites of
inflammation
The supposition that the selective accumulation
of distinct leukocyte subsets at sites of
inflammation is a result of endothelial selection
at the point of entry has largely been the prevailing
paradigm (Ref. 29). Selection within the tissue,
meditated by stromal determinants, has received
relatively little attention, despite their well-
defined role during lymphocyte development in
the BM and thymus. However, in order to persist,
an inflammatory infiltrate must result from an
imbalance between cell recruitment, proliferation,
emigration and death, and the stromal
environment plays an important role in this.
Resolution of the infiltrate depends on the
dominance of factors depleting the infiltrating cell
pool over factors increasing the infiltrating cell
pool. By contrast, persistence of inflammation
occurs when cell recruitment or proliferation is
ongoing, and emigration and death are inhibited
(Fig. 3).
After crossing post-capillary venules into
the subendothelial compartment, leukocytes
encounter a stromal microenvironment that is
quite distinct from that found in the vascular
compartment. It has emerged in recent years
that, while providing the anatomical environment
in which the immune response occurs, stromal
cells also directly participate in the induction
and effector phases of the response – particularly
in the switch from the innate to the acquired
immune response (Ref. 30). The T-cell expansion
seen after antigenic stimulation is followed by a
significant elimination phase, during which cell
numbers are restored to a near-basal state. These
homeostatic mechanisms depend on the induction
Figure 3. The dynamics of an inflammatory
infiltrate. The accumulation of leukocytes in any
tissue compartment depends on the dynamic balance
between cell recruitment, division, emigration and
death. (a) In the normal situation of acute resolving
inflammation, homeostasis between these cell events
is maintained, leading to resolution. (b) In chronic
persistent inflammation, abnormal accumulation of
leukocytes is caused by the inappropriate production
by stromal cells and fibroblasts of factors that are
either pro-retentive [e.g. stromal-cell-derived factor
1 (SDF-1)] or pro-survival [e.g. interferon β (IFN-β)]
(see also Fig. 1). Figure reproduced (with
modification) from Ref. 29, with permission from
Elsevier Science (© Copyright 2001, Elsevier
Science) (fig003cbb).
a Acute resolving inflammation
b Chronic persistent inflammation
The dynamics of an
inflammatory infiltrate
Published in Expert Reviews in Molecular 
Medicine by Cambridge University Press 2002
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of apoptosis, either by Fas-induced cell death or
by cytokine deprivation (Ref. 31). Cytokine
deprivation appears to be a particularly important
mechanism that ensures removal of lymphocytes
during the resolution of inflammation (Ref. 32).
The microenvironment formed by stromal
cells is bathed in cytokines, chemokines and
growth factors that actively condition the cellular
infiltrate (Refs 29, 33). Some of these mediators
actively promote cell survival by a range of anti-
apoptotic mechanisms, thereby contributing to the
persistence of inflammation. In particular,
cytokines of the IL-2 receptor common γ-chain
family, such as IL-2, IL-4, IL-7 and IL-15, are able
to inhibit apoptosis of activated T cells, most
probably by Bcl-2 induction (Ref. 34). A second
group, the type I interferons (IFN-α and IFN-β),
protect against both Fas-induced and cytokine-
deprivation-induced apoptosis by several
mechanisms, including the induction of Bcl-xL
expression and prevention of protein kinase C δ
translocation (Ref. 33). These two survival
mechanisms have quite different outcomes:
survival and proliferation in the case of the
common γ-chain cytokines, and survival and entry
into cell cycle arrest in the case of the interferons.
Far less is known about stromal mediators of
macrophage survival. In contrast to T cells,
macrophages appear to be relatively resistant to
survival factor deprivation, and  active migration
out of inflammatory sites has been demonstrated
(Refs 35, 36). The molecular mechanisms
mediating this process are unclear and are an area
of active research.
Clinical examples of inflammation
Although the chronic inflammatory diseases
rheumatoid arthritis, Sjögren’s syndrome and
multiple sclerosis show distinct pathologies and
tissue responses, common processes are likely
to underlie the inflammatory response since
therapeutic intervention with steroids is helpful
in many patients with these conditions. As
discussed below, each of these diseases requires
the recruitment of leukocytes, yet the way in
which these infiltrating leukocytes are organised
by the differing stromal microenvironment in the
three diseases is quite distinct.
Rheumatoid arthritis: chronic
inflammation in the joint
Rheumatoid arthritis is a chronic inflammatory
disease of unknown aetiology, characterised by
a disordered synovial microenvironment in
which there is hyperplasia of resident stromal
cells and a heavy infiltrate of haematopoietic cells
such as T and B cells (Refs 37, 38). A characteristic
feature of the inflammatory infiltrate is the
accumulation of lymphocytes into distinctive
micro-anatomical structures with architectural
features that strongly resemble lymphoid tissue
(Ref. 39). Lymphocytic activation is supposed to
be a primary factor in this process, but it has not
been possible to demonstrate direct evidence of a
specific target for autoimmune T cells. Indeed, the
heterogeneous antigenic reactivities observed
in rheumatoid arthritis joints might instead
reflect the occurrence of secondary, non-specific
sensitisation. A better understanding of the
underlying pathological processes in rheumatoid
arthritis might be achieved by investigating the
hypothesis that cellular recruitment to the joint
occurs episodically. Using the concepts detailed
above, we can ask (1) why the cells do not simply
leave the joint and (2) whether there are local
factors that maintain the architecture of an
inflammatory infiltrate.
The synovial microenvironment promotes
T-cell retention
The accumulation of T cells in the rheumatoid
joint has been shown to be due to contributions
from the active, chemokine-dependent retention
of T cells. It has recently been demonstrated that
synovial T cells highly express CXCR4, a receptor
not normally found on highly differentiated
CD45R0+ T cells in peripheral blood (Refs 40, 41).
CXCR4 expression is dependent on factors present
in the synovial microenvironment – particularly
transforming growth factor β (TGF-β).  SDF-1, the
ligand for CXCR4, is found at high levels within
the synovium and particularly on synovial
endothelial cells (Refs 40, 42, 43). Interestingly,
inhibiting the interaction between SDF-1 and
CXCR4 in a mouse model of collagen-induced
arthritis ameliorated the disease, suggesting that
inhibitors of SDF-1–CXCR4 interactions might
lead to clinical improvement in rheumatoid
arthritis (Ref. 44).
The synovial stromal microenvironment
prevents T-cell death
As mentioned above, removal of the vast majority
of immune cells that were recruited and expanded
during the active phase of disease is essential for
the successful resolution of an inflammatory
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response. The persistent leukocyte infiltrate in
the rheumatoid joint has been shown to be
partly a consequence of the inhibition of
apoptosis (Ref. 45). In rheumatoid arthritis,
synovial T cells are highly differentiated (CD45R0+
CD45RBdull) and should therefore die easily. This
process is partially inhibited by locally produced
cytokines and growth factors such as IFN-α and
IFN-β, produced by synovial fibroblasts and
macrophages (Ref. 46). This mechanism is likely
to be relevant for other cell types in other
pathological conditions, as these type I IFNs are
potent survival factors for a range of leukocyte
subsets (Ref. 47).
The conclusion from present studies can be
summarised as follows: the inflammatory
infiltrate in rheumatoid arthritis appears to persist
as a direct result of sustained recruitment,
inappropriate retention and enhanced survival of
cells, a process mediated by the abnormal
expression of stromal factors associated with the
local microenvironment (Switch 2, Fig. 1; Fig. 3).
Sjögren’s syndrome: chronic
inflammation in exocrine glands
The findings described above for rheumatoid
arthritis provide a potential explanation for why
rheumatoid tissues mimic many of the structural
features of stable supportive stromal cell niches
such as the BM and lymphoid tissue. Is this a
unique feature of rheumatoid arthritis or a
universal feature of many chronic inflammatory
diseases, particularly those where epithelial
tissues are inflamed?
Sjögren’s syndrome is characterised by the
accumulation of lymphocytes within salivary,
lachrymal and other exocrine glands in the
respiratory tract, gastrointestinal tract and vagina
(Ref. 48). The inflammatory infiltrate consists
predominantly of CD4+ T cells, with fewer CD8+
T cells, B cells and plasma cells. These first
appear as small clusters around ductal tissue,
later enlarging to form structures resembling
ectopic germinal centres (GCs). The development
of these ectopic lymphoid follicles has been
implicated in the pathogenesis of Sjögren’s
syndrome, as large amounts of autoantibodies are
a characteristic feature of the disease (Ref. 49). GCs
classically arise in primary B-cell follicles of
secondary lymphoid organs and provide a unique
microenvironment for B-cell maturation into
plasma cells (Ref. 50). Lymphoid aggregates with
ectopic GC-like structures (sometimes called
tertiary lymphoid tissue) are found in several
chronic inflammatory diseases. It remains unclear
whether these ectopic structures contain all the
necessary components required to generate a local
B-cell-driven response or simply represent a focus
point for the collection of autoantibody-producing
B cells that migrate into inflamed tissue from
nearby secondary lymphoid tissue (Refs 51, 52,
53, 54).
Why do ectopic GCs form in Sjögren’s
syndrome?
Recent studies have established a critical role for
TNF and lymphotoxin (LT) in the development
and maintenance of lymphoid tissue (Ref. 55).
The lack of normal lymphoid organs in mice
deficient in the lymphoid-homing chemokine
receptors CXCR4 and CXCR5 has also implicated
chemokines such as SDF-1 and BCA-1 in
lymphoid neogenesis (Refs 17, 56). Elegant studies
in transgenic mice overexpressing the constitutive
lymphoid chemokine BCA-1 have confirmed
that LT, TNF and BCA-1 act in a common
pathway of lymphoid neogenesis (Ref. 57).
Importantly, these studies have suggested that
similar molecular mechanisms might be
responsible for lymphoid development during
embryogenesis and the formation of lymphoid
aggregates in chronic inflammation, particularly
with regard to the production of chemokines.
In Sjögren’s syndrome, recent studies have
now shown that the accumulation of lymphocytes
in GC-like structures within inflamed tissue is also
associated with the ectopic expression of the
lymphoid-tissue homing chemokines BCA-1 and
SDF-1 (Ref. 58). Inflamed glands (but not control
tissue) from patients with Sjögren’s syndrome
expressed very high levels of BCA-1 on
endothelial-like structures found abundantly
throughout the inflamed tissue. In contrast to the
situation in rheumatoid arthritis, SDF-1 was
expressed on ductal epithelial tissue, rather than
on fibroblasts and endothelium (Ref. 58).
Taken together, these findings suggest that
the inappropriate temporal and spatial expression
of chemokines plays an important role in
determining the persistence and patterning of
lymphoid aggregates within chronically inflamed
tissues. They also provide strong support for
the hypothesis that the ectopic expression of
chemokines is a general feature that drives
leukocyte accumulation in chronic inflammatory
rheumatic diseases (Fig. 4).
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Multiple sclerosis: chronic inflammation
in the brain parenchyma
Whereas rheumatoid arthritis and Sjögren’s
syndrome are characterised by the presence of
large numbers of leukocytes within joints and
exocrine glands, respectively, other inflammatory
conditions, such as multiple sclerosis, often have
a much more restricted accumulation of
infiltrating inflammatory cells. Multiple sclerosis
is a disease of unknown aetiology characterised
by multifocal demyelination and polyphasic
inflammation in the central nervous system (CNS)
(reviewed in Ref. 59). Lymphocytic infiltration is
likely to be important for the formation of multiple
sclerosis plaques, but evidence of a specific target
for autoimmune T cells is lacking despite
strenuous attempts to define such targets.
Attention has therefore shifted to the mechanisms
regulating lymphocytic accumulation in the CNS.
Difficulties with heterogeneous pathological
features and lesion staging have made the
interpretation of specific inflammatory patterns
difficult (Ref. 60); nonetheless, it seems clear that
the infiltrates are composed of T cells, some B cells,
activated microglia and macrophages (Ref. 61).
The origin of these cells has been the subject of
some dispute: for a long time, the CNS was
considered an immunologically privileged site,
but research performed over the past decade has
indicated that this notion no longer holds true
(Ref. 62). Evidence of inflammatory cell trafficking
from the periphery into the CNS in humans has
been elegantly demonstrated in human studies
performed on allogeneic BM transplantation
Figure 4. Chronic inflammatory
microenvironments mimic lymphoid tissue.
Constitutive chemokines provide the link between
lymphoid neogenesis and chronic inflammation. (a)
In lymphoid tissue, tumour necrosis factor (TNF)
family members, such as TNF and lymphotoxin α/β
(LT- α/β), produced by infiltrating haematopoietic
cells, lead to the production of constitutive
chemokines (CCL19, CCL21, CXCL13) by stromal
cells, driving the formation of lymphoid tissue by
coordinating the further recruitment and distribution
of T cells, B cells and dendritic cells. (b) During
inflammation, other cytokines in addition to TNF, such
as interleukin 1 (IL-1) and interferon γ (IFN-γ), are
released by infiltrating haematopoietic cells, and this
leads to the production of inflammatory chemokines
(including CXCLs 2–5, CXCLs 1–11 and CX3CL1)
by the resident stromal cells such as fibroblasts,
endothelial and epithelial cells. Constitutive
chemokines such as CCL19, CCL21, CXCL12
and CXCL13 are not expressed during a normal,
resolving inflammatory response. However, the
inappropriate temporal and spatial production of
constitutive chemokines by stromal cells is an
intriguing feature of chronic persistent inflammatory
microenvironments. Indeed, ectopic production of
stromal-cell-derived factor 1 (SDF-1) and B-cell-
activating chemokine (BCA-1) and their receptors
CXCR4 and CXCR5 has been seen in the rheumatoid
arthritis synovium and Sjögren’s syndrome salivary
gland. These chemokines have been demonstrated
to be important in the formation of lymphoid tissue
(Ref. 97). If the basal production of constitutive
chemokines during inflammation is not tightly
regulated, this might lead to the superimposition of
lymphoid-like structures within inflamed tissue
(fig004cbb).
IFN-γ
TNF
IL-1
CCLs 2-5
CXCLs 1-11
CX3CL1
Plus ectopic CCL19, CCL21,
CXCL12, CXCL13
a Lymphoid tissue
b Chronic inflammation
Chronic inflammatory
microenvironments mimic
lymphoid tissue
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recipients (Ref. 63). These female recipients of
male donor cells develop a Y-chromosome-
bearing haematopoietic system. In situ
hybridisation using specific probes demonstrated
that all cells in the cerebrospinal fluid (CSF) and
the perivascular compartment, as well as the
infiltrating inflammatory cells, were donor
derived. By contrast, the parenchymal microglia
were host derived. These results closely mirror
rat radiation BM chimaera studies (Ref. 59) and
indicate that BM-derived cells continuously
patrol the CNS, whereas the parenchymal
microglial population appears very stable
(Refs  63, 64). Thus, the brain parenchyma
constitutes a quite different microenvironment to
that formed by the CSF and meninges.
The CNS in inflammatory conditions
promotes cellular retention
Little is known about the specific role of
chemokines in cellular migration across the
blood–brain barrier, and interpretation of
observational data is therefore difficult. Most T
cells in the CSF of both multiple sclerosis patients
and normal controls express the chemokine
receptor CXCR3, with some enrichment for
CCR5-expressing cells (Ref. 65) Similar patterns
are seen on perivascular lymphocytes in multiple
sclerosis autopsy material, but rarely in control
brain specimens. One of the ligands for CXCR3,
IFN-γ-inducible protein 10 (IP-10; CXCL10), is
produced by astrocytes in multiple sclerosis
lesions and it is hypothesised that this interaction
leads to the retention of CNS-infiltrating CXCR3+
cells (Ref. 66).
Chemokines also appear to play a role in
monocyte accumulation in multiple sclerosis.
Patients with neuroinflammatory disorders
(including multiple sclerosis) have increased
levels of macrophage inflammatory protein 1α
(MIP-1α; CCL3) in the CSF (Ref. 67),  and analysis
of CNS-infiltrating monocytes reveals that a
majority express the MIP-1α ligands CCR1 and
CCR5, with CCR5 expression persisting in the
multiple sclerosis lesion (Ref. 68). The importance
of these findings is highlighted by the observation
that T cells from multiple sclerosis patients display
an enhanced chemotactic response to CCL3 and
CCL5 but not to other chemokines (Ref. 69).
Prevention of T-cell death in the CNS?
Animal models of inflammatory disease in the
CNS clearly demonstrate that apoptosis is an
important factor in the resolution of the
inflammatory infiltrate (Ref. 70). Despite this,
lymphocyte apoptosis is not a prominent feature
in multiple sclerosis lesions (Refs 70, 71). As
lymphocytes persist in CNS infiltrates, it is likely
that local factors antagonise apoptotic processes;
however, the identity of such factors remains the
subject of speculation. Osteopontin [also known
as early T lymphocyte activation 1 (Eta-1)] has
emerged as a likely important player in multiple
sclerosis. This protein has multiple roles in the
maintenance of tissue homeostasis during
inflammatory processes, including macrophage
recruitment and differentiation, inhibition of
lymphocyte apoptosis and modulation of
cytokine responses (Ref. 72). Two recent studies
have demonstrated that osteopontin is present
in the CNS lesions in multiple sclerosis and
experimental autoimmune encephalomyelitis,
and plays an important role in sustaining
autoimmune destruction (Refs 73, 74). In view of
the many physiological roles for this agent, the
mechanism of action remains speculative. It is
tempting to consider that the established anti-
apoptotic actions of osteopontin also act to
modulate lymphocyte survival in the CNS.
Research in progress and
outstanding questions
Some common themes clearly emerge from these
studies. Chronically inflamed tissues often contain
lymphoid aggregates that share structural and
functional features of secondary lymphoid tissues,
with lymphoid follicles with GC reactions found
in a range of conditions including rheumatoid
arthritis and Sjögren’s syndrome (Refs 58, 75,
76, 77). The development of tertiary lymphoid
tissue shares common mechanisms with the
development of lymphoid organs. Experiments
using transgenic mice point to a pivotal role for
LT-α and its interaction with the TNF receptor
TNFR1 in the generation of lymph-node-like
structures in non-lymphoid tissues (Ref. 78). This
leads to the ectopic expression of SLC and BCA-1
and the formation of persistent inflammatory
infiltrates (Refs 77, 79). As a result of this research,
the inhibition of constitutive chemokines and their
receptors is now providing  a powerful new target
for anti-inflammatory therapies (Refs 44, 80, 81).
The transition from an acute inflammatory
response to long-lived acquired immunity is a
critical time for the immune system. Two
potentially competing processes occur in the
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inflammatory microenvironment. To generate a
productive response to antigen, immature
dendritic cells must sample antigen within
inflamed tissue and migrate to draining lymph
nodes for antigen presentation to T cells (Ref. 82).
Simultaneously, a range of stromal-tissue-derived
tissue repair mediators bathe the inflammatory
microenvironment. When these two processes
become subverted, the wrong cells (dendritic
cells/lymphocytes) accumulate in the wrong
place (tissue) at the wrong time (during the
resolution phase of inflammation). Chronically
inflamed tissue might then act as a ‘foster home’
for leukocytes, leading to inappropriate retention
and survival (Ref. 29). This might provide a
molecular explanation for the powerful effects of
anti-TNF-α therapy, since TNF-α is critically
involved in the positioning of lymphocytes within
tissue (Ref. 83).
Clinical implications
Large numbers of inflammatory mediators have
now been identified, and many are attractive
candidates for therapeutic manipulation in the
treatment of chronic inflammatory diseases.
Unfortunately, choosing which specific agent to
target is difficult, as the dynamic environment
makes it difficult to identify a specific hierarchy.
It is easy to antagonise a specific cytokine or
chemokine in vitro, when the assay read-out is
yet another biological mediator. It is altogether
more difficult to design an antagonist that
produces predictable biological effects in complex
microenvironments in vivo.
Changing the viewpoint and identifying
specific architectural features in diseased tissues
might be a more productive approach. The
presence of lymphoid aggregates in the
rheumatoid synovium with architectural features
that closely mimic secondary lymphoid tissues
implies that therapies should be designed to
counteract the formation of such structures. This
approach provides an attractive functional
explanation for the success of anti-TNF therapy
in rheumatoid arthritis, since it has recently
been demonstrated that TNF family members are
essential for lymph-node development (Refs 55,
84, 85). Anti-TNF therapy would therefore be
expected to modulate the microenvironmental
processes leading to lymphoid aggregate
formation in the synovium.
It is unlikely that anti-TNF therapy will be
useful for all chronic inflammatory conditions.
For example, multiple sclerosis forms an
interesting therapeutic contrast to rheumatoid
arthritis in that several attempts to treat
multiple sclerosis by TNF-α blockade worsened
disease rather than improved it (Refs 86, 87). The
reason for this is unknown, as prior human and
animal studies had suggested that TNF was an
important proinflammatory mediator in multiple
sclerosis (Refs 88, 89). The discrepancy might be
explained by the important role of TNF-α in nitric
oxide (NO) production, and the appreciation that
NO inhibits the proliferation of CNS T cells (Ref.
90). Inhibition of TNF-α would therefore be
proinflammatory in the CNS. By contrast,
although IFN-β is a licensed immunomodulator
in multiple sclerosis, elucidating its mechanism
of action has proved difficult because the agent
modulates a large number of genes that are
potentially relevant to multiple sclerosis (Refs
91, 92). IFN-β certainly increases the number
of IFN-γ-secreting cells and IFN-γ is an NO
inducer, thus providing a potential
microenvironmental explanation for the effect
(Refs 93, 94).
These examples highlight how the interplay
of complex microenvironmental controls found in
tissues can account for apparently contradictory
results during clinical trials. Further definition of
the hierarchical structures controlling tissue
homoeostasis in health and disease will provide
numerous exciting avenues for the development
of therapies to control chronic inflammatory
conditions.
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Further reading, resources and contacts
Two reviews highlighting the mechanisms of leukocyte accumulation in inflammatory diseases and possible
therapeutic avenues:
Westermann, J., Engelhardt, B. and Hoffmann, J.C. (2001) Migration of T cells in vivo: molecular
mechanisms and clinical implications. Ann Intern Med 135, 279-295, PubMed: 21402291
Pope, R.M. (2002) Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol 2, 527-535,
PubMed: 22088851
Review covering many issues in lymphoid homeostasis:
Van Parijs, L. and Abbas, A.K. (1998) Homeostasis and self-tolerance in the immune system: turning
lymphocytes off. Science 280, 243-248, PubMed: 98202600
The Chemokine Website (Kumamoto Univeristy School of Medicine, Japan) is frequently updated and
provides links to database resources:
http://cytokine.medic.kumamoto-u.ac.jp/CFC/CK/chemokine.html
Some of the concepts in this article are highlighted at the Birmingham Department of Rheumatology
website:
http://rheuma.bham.ac.uk/NewSite/department/site.htm
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Figures
Figure 1. Two switches are involved in the development of persistent chronic inflammation (fig001cbb).
Figure 2. Chemokine receptors and chemokine ligand specificity (fig002cbb).
Figure 3. The dynamics of an inflammatory infiltrate (fig003cbb).
Figure 4. Chronic inflammatory microenvironments mimic lymphoid tissue (fig004cbb).
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